SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Ghost Tree Capital, LLC

CIK 0001595851 · 667 MADISON AVENUE, 5TH FLOOR, SUITE 12, NEW YORK, NY, 10065 · 6467790120

Reported Value
$319M
Q2 2024
Positions
63
Filings on Record
32
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Ghost Tree Capital, LLC reported $319M in U.S.-listed holdings across 63 positions for Q2 2024.

Its largest position, Biohaven, represents 5.3% of the portfolio.

Compared with Q1 2024, the fund opened 11 new positions and exited 19.

Portfolio Metrics

Turnover
+30.6%
vs prior filed quarter
Top-10 Concentration
+36.7%
share of reported value
Largest Position
+5.3%
Biohaven
New / Exited
11 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $285MQ4 ’18Q1 ’19: $369MQ2 ’19: $477MQ3 ’19: $394MQ3 ’19Q4 ’19: $529MQ1 ’20: $377MQ2 ’20: $379MQ2 ’20Q3 ’20: $346MQ4 ’20: $449MQ1 ’21: $425MQ1 ’21Q2 ’21: $364MQ3 ’21: $342MQ4 ’21: $279MQ4 ’21Q1 ’22: $461MQ2 ’22: $192MQ3 ’22: $356MQ3 ’22Q4 ’22: $234MQ1 ’23: $338MQ2 ’23: $303MQ2 ’23Q3 ’23: $304MQ4 ’23: $306MQ1 ’24: $361MQ1 ’24Q2 ’24: $319MQ3 ’24: $331Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 83.9%Other: 16.1%
  • Common Stock · 83.9% · $268M
  • Other · 16.1% · $51M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ASCENDIS PHARMA A/SNEW+86.7K86.7K+$12M$12M
CATXPERSPECTIVE THERAPEUTICS INCNEW+925.0K925.0K+$9M$9M
RZLTREZOLUTE INCNEW+1.42M1.42M+$6M$6M
KRROKORRO BIO INCNEW+100.0K100.0K+$3M$3M
NUVBNUVATION BIO INCNEW+1.15M1.15M+$3M$3M
ANNXANNEXON INCNEW+524.5K524.5K+$3M$3M
JANXJANUX THERAPEUTICS INCNEW+50.0K50.0K+$2M$2M
PROQR THRAPEUTICS N VNEW+900.0K900.0K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BIOHAVEN LTDCOM5.33%$17M490.0K
2MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD4.13%$13M300.0K
3SLNOEURSOLENO THERAPEUTICS INChistory →COM3.83%$12M300.0K
4AXSMAXSOME THERAPEUTICS INChistory →COM3.78%$12M150.0K
5ASCENDIS PHARMA A/SSPONSORED ADR3.70%$12M86.7K
6PCVXVAXCYTE INChistory →COM3.55%$11M150.0K
7CRNXCRINETICS PHARMACEUTICALS INhistory →COM3.37%$11M240.0K
8ROIVANT SCIENCES LTDSHS3.31%$11M1.00M
9CATXPERSPECTIVE THERAPEUTICS INChistory →COM NEW2.89%$9M925.0K
10TGTXTG THERAPEUTICS INChistory →COM2.79%$9M500.0K
11SRPTSAREPTA THERAPEUTICS INChistory →COM2.72%$9M55.0K
12CGONCG ONCOLOGY INChistory →COM2.57%$8M260.0K
13CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW2.48%$8M175.0K
14VRDNVIRIDIAN THERAPEUTICS INChistory →COM2.39%$8M587.7K
15SNDXSYNDAX PHARMACEUTICALS INChistory →COM2.25%$7M350.0K
16IMVTIMMUNOVANT INChistory →COM2.15%$7M260.0K
17TARSTARSUS PHARMACEUTICALS INChistory →COM2.00%$6M235.0K
18PHATPHATHOM PHARMACEUTICALS INChistory →COM1.94%$6M600.0K
19RZLTREZOLUTE INChistory →COM NEW1.91%$6M1.42M
20OLMAOLEMA PHARMACEUTICALS INChistory →COM1.86%$6M550.0K
21SYRESPYRE THERAPEUTICS INChistory →COM NEW1.84%$6M250.2K
22ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.71%$5M22.5K
23APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.62%$5M135.0K
24VKTXVIKING THERAPEUTICS INChistory →COM1.58%$5M95.0K
25RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.51%$5M117.4K
26IM8NINSMED INChistory →COM PAR $.011.36%$4M65.0K
272655787DBLUEPRINT MEDICINES CORPhistory →COM1.35%$4M40.0K
28YB4PSAVARA INChistory →COM1.33%$4M1.05M
29TNYATENAYA THERAPEUTICS INChistory →COM1.31%$4M1.35M
30REPLREPLIMUNE GROUP INChistory →COM1.27%$4M450.0K
31ENGENE HOLDINGS INCCOM1.24%$4M420.3K
32ACADACADIA PHARMACEUTICALS INChistory →COM1.14%$4M225.0K
33BBIOBRIDGEBIO PHARMA INChistory →COM1.11%$4M140.0K
34KRROKORRO BIO INChistory →COM1.06%$3M100.0K
35NUVBNUVATION BIO INChistory →COM CL A1.05%$3M1.15M
36HELIX ACQUISITION CORP IICL A ORD SHS0.96%$3M300.0K
37TSHATAYSHA GENE THERAPIES INCCOM SHS0.88%$3M1.25M
38CABACABALETTA BIO INCCOM0.87%$3M370.9K
39NGNENEUROGENE INCCOM0.80%$3M70.0K
40JANXJANUX THERAPEUTICS INCCOM0.66%$2M50.0K
41ARVNARVINAS INCCOM0.63%$2M75.0K
42RGNXREGENXBIO INCCOM0.62%$2M170.0K
43CYTKCYTOKINETICS INCCOM NEW0.56%$2M33.2K
44ELEVATION ONCOLOGY INCCOM0.51%$2M600.0K
45KRYSKRYSTAL BIOTECH INCCOM0.49%$2M8.5K
46ANNXANNEXON INCCOM0.48%$2M310.0K
47PROQR THRAPEUTICS N VSHS EURO0.47%$1M900.0K
48ATYRATYR PHARMA INCCOM NEW0.39%$1M800.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$331M54Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$319M63Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$361M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$306M52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$304M70Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$303M57Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$338M58May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$234M35Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$356M44Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$192M34Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$461M42May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$279M47Feb 16, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M60Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M52Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$425M50May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$449M43Feb 18, 2021RESTATEMENTchanges · EDGAR ↗
Q3 2020$346M47Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$379M43Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$377M49May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$529M53Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$394M44Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$477M43Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$369M39May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$285M39Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.